Helus Pharma (NASDAQ: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists for serious mental health disorders, announced the appointment of Michael Cola as Chief Executive Officer, effective immediately. The appointment comes as the company advances its pipeline toward key clinical and corporate milestones.
Helus Pharma, the commercial operating name of Cybin Inc. (founded in 2019), is committed to developing proprietary NSAs—novel serotonergic agonists—synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. These compounds are intended to address the unmet need for people suffering from depression, anxiety, and other mental health conditions.
The company’s clinical pipeline includes HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, and HLP004, a proprietary NSA in Phase 2 for generalized anxiety disorder. Phase 2 data for HLP004 is expected this quarter, while Phase 3 topline data for HLP003 is expected in Q4 2026. Helus Pharma also maintains an extensive research portfolio of investigational NSAs.
The company operates in Canada, the United States, the United Kingdom, and Ireland, and continues to expand its global intellectual property portfolio while transitioning toward later-stage development, regulatory engagement, and long-term commercial planning.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://menafn.com/1110722669/Biomednewsbreaks-Helus-PharmaTM-NASDAQ-HELP-Cboe-CA-HELP-Appoints-Michael-Cola-As-Chief-Executive-Officer